Reflux disease and Barrett's esophagus

Area of Science:

• Gastroenterology
• Oncology

Background:

• Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder characterized by gastric content reflux into the esophagus.
• Proton-pump inhibitors (PPIs) are the standard medical treatment, with antireflux surgery an option for refractory cases.
• Esophageal adenocarcinoma, a rare complication of GERD, arises from Barrett's esophagus, a precursor lesion.

Purpose of the Study:

• To review the current understanding of GERD, Barrett's esophagus development, and associated cancer risks.
• To outline appropriate clinical management strategies for GERD patients with Barrett's esophagus, including surveillance and treatment options.

Main Methods:

• Review of existing literature on GERD, Barrett's esophagus, and esophageal adenocarcinoma.
• Analysis of risk factors such as Barrett's segment length and hiatal hernia size.
• Discussion of current and emerging endoscopic surveillance and treatment modalities.

Main Results:

• Genetic factors influence individual risk for Barrett's esophagus and adenocarcinoma.
• Barrett's esophagus length and hiatal hernia size are associated with increased risk of high-grade dysplasia and adenocarcinoma.
• Endoscopic surveillance every 3 years is recommended for GERD patients without dysplasia.

Conclusions:

• GERD management involves medical therapy, surgery, and surveillance for complications.
• Endoscopic surveillance and intervention are crucial for managing Barrett's esophagus and preventing esophageal adenocarcinoma.
• Curative endoscopic resection and mucosal ablation show promise for high-grade dysplasia but require further clinical investigation.